Abstract
Background
Accumulating evidence indicates that multiple genetic factors are involved in the pathogenesis of primary biliary cirrhosis (PBC). The aim of this study was to investigate whether polymorphisms of the integrin αV subunit gene (ITGAV), a component of integrin αVβ6, which plays an important role in the process of fibrosis, are associated with susceptibility to the onset and/or progression of PBC.
Methods
In the primary study, eight tag single nucleotide polymorphisms (SNPs) in ITGAV were analyzed by polymerase chain reaction (PCR)-restriction fragment length polymorphism, direct DNA sequencing, or high-resolution melting curve analysis in 309 Japanese patients with PBC who were registered in the National Hospital Organization Study Group for Liver Disease in Japan (PBC cohort I) and 293 gender-matched healthy Japanese volunteers (control subjects). For the replication study, 35 PBC patients who progressed to end-stage hepatic failure and underwent liver transplantation (PBC cohort II) were also analyzed.
Results
Three tag SNPs (rs3911238, rs10174098, and rs1448427) in ITGAV were significantly associated with the severe progression of PBC, but not with susceptibility to the onset of PBC, in the primary study (PBC cohort I). Among these SNPs, rs1448427 was also significantly associated with the severe progression to end-stage hepatic failure in the replication study of PBC patients who underwent liver transplantation (PBC cohort II).
Conclusions
ITGAV is a genetic determinant for the severe progression of PBC in Japanese patients. Genetic polymorphisms of ITGAV may be useful for identifying high-risk Japanese PBC patients, including those who will require liver transplantation, at the time of initial diagnosis.
Similar content being viewed by others
References
Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med. 2005;353:1261–73.
Poupon R. Primary biliary cirrhosis: a 2010 update. J Hepatol. 2010;52:745–58.
Corpechot C, Carrat F, Bahr A, Chretien Y, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology. 2005;128:297–303.
Brind AM, Bray GP, Portmann BC, Williams R. Prevalence and pattern of familial disease in primary biliary cirrhosis. Gut. 1995;36:615–7.
Selmi C, Invernizzi P, Zuin M, Podda M, Seldin MF, Gershwin ME. Genes and (auto)immunity in primary biliary cirrhosis. Genes Immun. 2005;6:543–56.
Selmi C, Mayo MJ, Bach N, Ishibashi H, Invernizzi P, Gish RG, et al. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology. 2004;127:485–92.
Hirschfield GM, Liu X, Xu C, Lu Y, Xie G, Lu Y, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med. 2009;360:2544–55.
Nakamura M, Yasunami M, Kondo H, Horie H, Aiba Y, Komori A, et al. Analysis of HLA-DRB1 polymorphisms in Japanese patients with primary biliary cirrhosis (PBC): the HLA-DRB1 polymorphism determines the relative risk of antinuclear antibodies for disease progression in PBC. Hepatol Res. 2010;40:494–504.
Agarwal K, Jones DEJ, Daly AK, James OFW, Vaidya B, Pearce S, et al. CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. J Hepatol. 2000;32:538–41.
Juran BD, Atkinson EJ, Schlicht EM, Fridley BL, Lazaridis KN. Primary biliary cirrhosis is associated with a genetic variant in the 3′ flanking region of the CTLA4 gene. Gastroenterology. 2008;135:1200–6.
Joshita S, Umemura T, Yoshizawa K, Katsuyama Y, Tanaka E, Nakamura M, et al. Association analysis of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with primary biliary cirrhosis in Japanese patients. J Hepatol. 2010;53:537–41.
Tanaka A, Nezu S, Uegaki S, Kikuchi K, Shibuya A, Miyakawa H, et al. Vitamin D receptor polymorphisms are associated with increased susceptibility to primary biliary cirrhosis in Japanese and Italian populations. J Hepatol. 2009;50:1202–9.
Donaldson P, Agarwal K, Craggs A, Craig W, James O, Jones D. HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: associations with disease progression and disease susceptibility. Gut. 2001;48:397–402.
Hirschfield GM, Liu X, Han Y, Gorlov IP, Lu Y, Xu C, et al. Variants at IRF5-TNPO3, 17q12–21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet. 2010;42:655–7.
Liu X, Invernizzi P, Lu Y, Kosoy R, Lu Y, Bianchi I, et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet. 2010;42:658–60.
Poupon R, Ping C, Chrétien Y, Corpechot C, Chazouillères O, Simon T, et al. Genetic factors of susceptibility and of severity in primary biliary cirrhosis. J Hepatol. 2008;49:1038–45.
Ohishi Y, Nakamura M, Iio N, Higa S, Inayoshi M, Aiba Y, et al. Single-nucleotide polymorphism analysis of the multidrug resistance protein 3 gene for the detection of clinical progression in Japanese patients with primary biliary cirrhosis. Hepatology. 2008;48:853–62.
Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209–18.
Huttenlocher A, Ginsberg MH, Horwitz AF. Modulation of cell migration by integrin-mediated cytoskeletal linkages and ligand-binding affinity. J Cell Biol. 1996;134:1551–62.
Luo B, Springer TA. Integrin structures and conformational signaling. Curr Opin Cell Biol. 2006;18:579–86.
Busk M, Pytela R, Sheppard D. Characterization of the integrin avb6 as a fibronectin-binding protein. J Biol Chem. 1992;267:5790–6.
Prieto AL, Edelman GM, Crossin KL. Multiple integrins mediate cell attachment to cytotactin/tenascin. Proc Natl Acad Sci USA. 1993;90:10154–8.
Margadant C, Sonnenberg A. Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing. EMBO Rep. 2010;11:97–105.
Patsenker E, Popov Y, Stickel F, Jonczyk A, Goodman SL, Schuppan D. Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology. 2008;135:660–70.
Popov Y, Patsenker E, Stickel F, Zaks J, Bhaskar KR, Niedobitek G, et al. Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol. 2008;48:453–64.
Lee SK, Kim M, Cheong JY, Cho SW, Yang S, Kwack KB. Integrin alpha V polymorphisms and haplotypes in a Korean population are associated with susceptibility to chronic hepatitis and hepatocellular carcinoma. Liver Int. 2009;29:187–95.
Scheuer P. Primary biliary cirrhosis. Proc R Soc Med. 1967;60:1257–60.
Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263–5.
Wittwer CT, Reed GH, Gundry CN, Vandersteen JG, Pryor RJ. High-resolution genotyping by amplicon melting analysis using LCGreen. Clin Chem. 2003;49:853–60.
Wang B, Dolinski BM, Kikuchi N, Leone DR, Peters MG, Weinreb PH, et al. Role of alphavbeta6 integrin in acute biliary fibrosis. Hepatology. 2007;46:1404–12.
Hirai Y, Nelson CM, Yamazaki K, Takebe K, Przybylo J, Madden B, et al. Non-classical export of epimorphin and its adhesion to αV-integrin in regulation of epithelial morphogenesis. J Cell Sci. 2007;120:2032–43.
Segawa D, Miura K, Goto T, Ohshima S, Mikami K, Yoneyama K, et al. Distribution and isoforms of epimorphin in carbon tetrachloride-induced acute liver injury in mice. J Gastroenterol Hepatol. 2005;20:1769–80.
Yoshino R, Miura K, Segawa D, Hirai Y, Goto T, Ohshima S, et al. Epimorphin expression and stellate cell status in mouse liver injury. Hepatol Res. 2006;34:238–49.
Zhou J, Zhao L, Qin L, Wang J, Jia Y, Yao H, et al. Epimorphin regulates bile duct formation via effects on mitosis orientation in rat liver epithelial stem-like cells. PLoS One. 2010;5:e9732.
Vleggaar FP, Van Buuren HR, Zondervan PE, Ten Kate FJW, Hop WCJ, Adang R, et al. Jaundice in non-cirrhotic primary biliary cirrhosis: the premature ductopenic variant. Gut. 2001;49:276–81.
Hollis-Moffatt JE, Rowley KA, Phipps-Green AJ, Merriman ME, Dalbeth N, Gow P, Harrison AA, et al. The ITGAV rs3738919 variant and susceptibility to rheumatoid arthritis in four Caucasian sample sets. Arthritis Res Ther. 2009;11:R152.
Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology. 2007;45:118–27.
Acknowledgments
This study was supported by Health and Labour Sciences Research Grants for Research on Measures for Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan (M. Nakamura); a Grant-in-Aid for Scientific Research (C) (KAKENHI No. 20590545) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (K. Omagari); and the president’s discretionary fund of Nagasaki University, Japan (K. Tsukamoto). The authors thank the PBC patients and healthy volunteers for participating in this study, and also thank members of the PBC Study Group in NHSOLJ: Dr. Akira Saito (NHO Nishisaitama Chuo Hospital), Dr. Naohiko Masaki (Kokusai Medical Center), Dr. Michiyasu Yagura (NHO Tokyo Hospital), Drs. Yukio Watanabe and Yoko Nakamura (NHO Sagamihara Hospital), Drs. Koichi Honda and Toyokichi Muro (NHO Oita Medical Center), Dr. Yoshinobu Fukushima (NHO Kyushu Medical Center), Drs. Masaaki Shimada and Noboru Hirashima (NHO Nagoya Medical Center), Dr. Masakazu Kobayashi (NHO Matsumoto Medical Center), Dr. Yukio Ohara (NHO Hokkaido Medical Center), Dr. Tatsuji Komatsu (NHO Yokohama Medical Center), Dr. Hajime Ota (NHO Kanazawa Medical Center), Drs. Hiroshi Kohno and Hirotaka Kouno (NHO Kure Medical Center), Dr. Haruhiro Yamashita (NHO Okayama Medical Center), Dr. Takeaki Sato (NHO Kokura Medical Center), Dr. Toshiki Komeda (NHO Kyoto Medical Center), Dr. Michiaki Koga (NHO Ureshino Medical Center), Dr. Masahiko Takahashi (NHO Tokyo Medical Center), Dr. Tetsuo Yamamoto (NHO Yonago Medical Center), Dr. Kazuhiro Sugi (NHO Kumamoto Medical Center), Dr. Michio Kato (NHO Minami Wakayama Medical Center), Dr. Eiichi Takezaki (NHO Higashi Hiroshima Medical Center), Dr. Hiroshi Mano (NHO Sendai Medical Center), Dr. Hideo Nishimura (NHO Douhoku Hospital), Dr. Eiji Mita (NHO Osaka Medical Center), Dr. Hironori Sakai (NHO Beppu Medical Center), and Drs. Shinya Nagaoka, Seigo Abiru, and Koji Yano (NHO Nagasaki Medical Center), for providing blood samples and clinical information from PBC patients.
Conflict of interest
None.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Inamine, T., Nakamura, M., Kawauchi, A. et al. A polymorphism in the integrin αV subunit gene affects the progression of primary biliary cirrhosis in Japanese patients. J Gastroenterol 46, 676–686 (2011). https://doi.org/10.1007/s00535-010-0351-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00535-010-0351-0